| Autor: |
Mateu-Bosch, A., Segur-Bailach, E., García-Villoria, J., Gea-Sorlí, S., Ruiz, I., del Rey, J., Camps, J., Guitart-Mampel, M., Garrabou, G., Tort, F., Ribes, A., Fillat, C. |
| Zdroj: |
Gene Therapy; January 2024, Vol. 31 Issue: 1-2 p12-18, 7p |
| Abstrakt: |
Glutaric Aciduria type I (GA1) is a rare neurometabolic disorder caused by mutations in the GDCHgene encoding for glutaryl-CoA dehydrogenase (GCDH) in the catabolic pathway of lysine, hydroxylysine and tryptophan. GCDH deficiency leads to increased concentrations of glutaric acid (GA) and 3-hydroxyglutaric acid (3-OHGA) in body fluids and tissues. These metabolites are the main triggers of brain damage. Mechanistic studies supporting neurotoxicity in mouse models have been conducted. However, the different vulnerability to some stressors between mouse and human brain cells reveals the need to have a reliable human neuronal model to study GA1 pathogenesis. In the present work we generated a GCDHknockout (KO) in the human neuroblastoma cell line SH-SY5Y by CRISPR/Cas9 technology. SH-SY5Y-GCDHKO cells accumulate GA, 3-OHGA, and glutarylcarnitine when exposed to lysine overload. GA or lysine treatment triggered neuronal damage in GCDH deficient cells. SH-SY5Y-GCDHKO cells also displayed features of GA1 pathogenesis such as increased oxidative stress vulnerability. Restoration of the GCDH activity by gene replacement rescued neuronal alterations. Thus, our findings provide a human neuronal cellular model of GA1 to study this disease and show the potential of gene therapy to rescue GCDH deficiency. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink